Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled…
Search
Tag: nominates
